Spots Global Cancer Trial Database for psma
Every month we try and update this database with for psma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | NCT06004661 | Metastatic Cast... | AAA617 68Ga-PSMA-11 | 18 Years - | Novartis | |
| Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT06377683 | Metastatic Cast... | 177Lu-Dansyl-PS... | 21 Years - | The First Affiliated Hospital of Xiamen University | |
| Intervention of CAR-T Against Cervical Cancer | NCT03356795 | Cervical Cancer | Cervical cancer... | 18 Years - 70 Years | Shenzhen Geno-Immune Medical Institute | |
| 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer | NCT04689828 | Prostatic Neopl... | 177Lu-PSMA-617 68Ga-PSMA-11 ARDT Best supportive... | 18 Years - | Novartis | |
| Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer | NCT05369000 | Metastatic Cast... | LAVA-1207 LAVA-1207 plus ... | 18 Years - | Lava Therapeutics | |
| A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer | NCT00992745 | Prostate Cancer | 123-I-MIP-1072 111-In capromab... 123-I-MIP-1072 | 18 Years - | Molecular Insight Pharmaceuticals, Inc. | |
| Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer | NCT03976843 | Prostate Cancer | 18F-DCFPyL | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment | NCT04647526 | Metastatic Cast... | [Lu-177]-PNT200... Abiraterone Enzalutamide | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| PSMA-specific CAR-T Cell Therapy | NCT04429451 | PSMA Positive T... | 4SCAR-PSMA T ce... | 1 Year - 75 Years | Shenzhen Geno-Immune Medical Institute | |
| the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma | NCT04104607 | Castration-Resi... | CC-1, PSMAxCD3 | 18 Years - | University Hospital Tuebingen | |
| First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT06217822 | Advanced Metast... Prostate Specif... | 225Ac-PSMA-Tril... Tris-POC (BAY26... 111In-PSMA-Tril... | 18 Years - | Bayer | |
| Evaluation of Fapi-pet in Prostate Cancer. | NCT05192694 | Prostate Cancer | Computed tomogr... | 18 Years - 100 Years | Helsinki University Central Hospital | |
| Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study) | NCT04833517 | Prostate Cancer... Castration Resi... Advanced Prosta... | 18 Years - | Universität des Saarlandes | ||
| EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T | NCT05521412 | Prostate Cancer Metastatic Cast... | [ 161 Tb]Tb PSM... | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| 177Lu-LNC1011 in Patients With Metastatic Castration-resistant Prostate Cancer | NCT06250244 | Metastatic Cast... | 177Lu-LNC1011 | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| 18F-DCFPyL PET/CT in Hepatocellular Carcinoma | NCT05009979 | Hepatocellular ... | F18-FDG MRI CT F18-DCFPyL | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | NCT04221542 | Prostate Cancer | AMG 509 Abiraterone Enzalutamide | 18 Years - | Amgen | |
| 177Lu-LNC1011 in Patients With Metastatic Castration-resistant Prostate Cancer | NCT06250244 | Metastatic Cast... | 177Lu-LNC1011 | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| Intervention of CAR-T Against Cervical Cancer | NCT03356795 | Cervical Cancer | Cervical cancer... | 18 Years - 70 Years | Shenzhen Geno-Immune Medical Institute | |
| PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment | NCT00694551 | Prostate Cancer | Peptide Vaccine Poly IC-LC | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| 99mTc-MIP-1404 SPECT/CT in Primary Staging of Prostate Cancer | NCT06219746 | Prostate Cancer | PSMA-imaging | 18 Years - | Turku University Hospital | |
| Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT06377683 | Metastatic Cast... | 177Lu-Dansyl-PS... | 21 Years - | The First Affiliated Hospital of Xiamen University | |
| A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer | NCT05658003 | Metastatic Cast... | [177Lu]Lu-PSMA-... ARDT [68Ga]Ga-PSMA-1... Best supportive... | 18 Years - | Novartis | |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC | NCT05670106 | Metastatic Cast... | [177Lu]Lu-PSMA-... Best supportive... 68Ga-PSMA-11 | 18 Years - | Novartis | |
| 99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer | NCT06419348 | Prostate Cancer... PSMA SPECT | 99mTc-QULIC-5-P... | 18 Years - | First Affiliated Hospital of Chongqing Medical University | |
| CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma | NCT03427476 | Renal Cell Carc... | CTT1057 | 18 Years - | Cancer Targeted Technology | |
| 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer | NCT03181867 | Prostate Neopla... Prostatic Cance... Prostate Cancer Cancer Of Prost... Metastatic Pros... | 18F-DCFPyL 18F-FDG PSMA-11 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor | NCT05616650 | Prostatic Neopl... Prostate Cancer Prostate Adenoc... | 18F-DCFPyL Stereotactic Bo... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer | NCT05712174 | Oncology Prostate Cancer | [18]F-PSMA-1007 | 18 Years - | AHS Cancer Control Alberta | |
| Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer | NCT05653856 | Metastasis From... | 64Cu-PSMA I&T | 18 Years - | Curium US LLC | |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC | NCT05670106 | Metastatic Cast... | [177Lu]Lu-PSMA-... Best supportive... 68Ga-PSMA-11 | 18 Years - | Novartis | |
| Diagnostic Accuracy and Performance of 18F-PSMA-1007 | NCT04986280 | Prostate Cancer | [18F]PSMA-1007 | 18 Years - | Insel Gruppe AG, University Hospital Bern | |
| Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7 | NCT05622162 | Prostate Cancer 18F- Fluorochol... PSMA PET Radiotherapy Prostatectomy Tumor of Prosta... | Radiopharmaceut... Radiopharmaceut... | 18 Years - | ITEL Telecomunicazioni Srl | |
| [Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients | NCT04693169 | Prostate Cancer | 11C-Choline | 18 Years - 90 Years | Peking University Cancer Hospital & Institute | |
| Ga-68-PSMA-11 in Men With Prostate Cancer | NCT05744115 | Prostate Cancer Prostate Adenoc... | Ga-68-PSMA-11 | 18 Years - | Harry S. Truman Memorial Veterans' Hospital | |
| 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer | NCT04689828 | Prostatic Neopl... | 177Lu-PSMA-617 68Ga-PSMA-11 ARDT Best supportive... | 18 Years - | Novartis | |
| Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer | NCT04085991 | Prostate Cancer Prostate Adenoc... Prostatic Neopl... Metastatic Pros... Metastatic Pros... Metastatic Pros... | 131I-PSMA-1095 ... | 18 Years - | Sir Mortimer B. Davis - Jewish General Hospital | |
| PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer | NCT04560725 | Prostate Cancer | 11C-Choline | 18 Years - 90 Years | Peking University Cancer Hospital & Institute | |
| Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor | NCT05616650 | Prostatic Neopl... Prostate Cancer Prostate Adenoc... | 18F-DCFPyL Stereotactic Bo... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Radio-guided Surgery With DROP-IN Beta Probe for 68Ga-PSMA, in High-risk Prostate Cancer Patients Eligible for Robotic-assisted Radical Prostatectomy. | NCT05596851 | Prostate Cancer Positron Emissi... PSMA | 18 Years - | European Institute of Oncology | ||
| 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer | NCT05204927 | Metastasis From... | 177Lu-PSMA-I&T Abiraterone wit... | 18 Years - | Curium US LLC | |
| ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer | NCT04662580 | Prostate Cancer | ARX517 | 18 Years - | Ambrx, Inc. | |
| Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer | NCT03976843 | Prostate Cancer | 18F-DCFPyL | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Diagnostic Accuracy and Performance of 18F-PSMA-1007 | NCT04986280 | Prostate Cancer | [18F]PSMA-1007 | 18 Years - | Insel Gruppe AG, University Hospital Bern | |
| The Combination of PSMA-PET/MR and p2PSA in Early Diagnosis of Prostate Cancer | NCT05822726 | Prostate Cancer PSMA p2PSA | Prostate biopsy | 18 Years - 85 Years | Ruijin Hospital | |
| 18F-DCFPyL PET/CT in Hepatocellular Carcinoma | NCT05009979 | Hepatocellular ... | F18-FDG MRI CT F18-DCFPyL | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT | NCT03861676 | Prostate Cancer | Focal brachythe... (18F)DCFPyL | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC | NCT04720157 | Prostatic Neopl... | 177Lu-PSMA-617 68Ga-PSMA-11 ARDT ADT | 18 Years - | Novartis | |
| Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System | NCT05437679 | High Risk Prost... Biochemically R... Castration-resi... Prostate Cancer | Blood collectio... | 18 Years - | Angle plc | |
| ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer | NCT04662580 | Prostate Cancer | ARX517 | 18 Years - | Ambrx, Inc. | |
| A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy | NCT05547061 | Prostate Cancer mCRPC | Lu-177-DGUL Ga-68-NGUL | 19 Years - | Cellbion Co., Ltd. | |
| ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer | NCT04662580 | Prostate Cancer | ARX517 | 18 Years - | Ambrx, Inc. | |
| 99mTc-MIP-1404 SPECT/CT in Primary Staging of Prostate Cancer | NCT06219746 | Prostate Cancer | PSMA-imaging | 18 Years - | Turku University Hospital | |
| A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy | NCT01279785 | Prostate Cancer | 123I-MIP-1072 | 18 Years - | Molecular Insight Pharmaceuticals, Inc. | |
| Evaluation of Fapi-pet in Prostate Cancer. | NCT05192694 | Prostate Cancer | Computed tomogr... | 18 Years - 100 Years | Helsinki University Central Hospital | |
| A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer | NCT03822871 | Prostate Cancer | CTT1403 CTT1057 68Ga-PSMA-11 | 18 Years - | Cancer Targeted Technology | |
| Hepatocellular Carcinoma Imaging Using PSMA PET/CT | NCT05095519 | Hepatocellular ... | 18F-DCFPyL | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer | NCT04560725 | Prostate Cancer | 11C-Choline | 18 Years - 90 Years | Peking University Cancer Hospital & Institute | |
| A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy | NCT05547061 | Prostate Cancer mCRPC | Lu-177-DGUL Ga-68-NGUL | 19 Years - | Cellbion Co., Ltd. | |
| First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT06217822 | Advanced Metast... Prostate Specif... | 225Ac-PSMA-Tril... Tris-POC (BAY26... 111In-PSMA-Tril... | 18 Years - | Bayer | |
| An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC | NCT04720157 | Prostatic Neopl... | 177Lu-PSMA-617 68Ga-PSMA-11 ARDT ADT | 18 Years - | Novartis | |
| 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer | NCT03181867 | Prostate Neopla... Prostatic Cance... Prostate Cancer Cancer Of Prost... Metastatic Pros... | 18F-DCFPyL 18F-FDG PSMA-11 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer | NCT06235099 | Prostate Cancer Prostate Adenoc... Biochemical Rec... | Copper Cu 64 PS... | 18 Years - | Curium US LLC | |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer | NCT06235151 | Prostate Cancer Prostate Adenoc... | Copper Cu 64 PS... | 18 Years - | Curium US LLC | |
| Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7 | NCT05622162 | Prostate Cancer 18F- Fluorochol... PSMA PET Radiotherapy Prostatectomy Tumor of Prosta... | Radiopharmaceut... Radiopharmaceut... | 18 Years - | ITEL Telecomunicazioni Srl |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
